2016 Year End Brought Closure to Many Diagnostic Deals

As 2016 came to a close, so too did a significant number of business deals involving diagnostic companies, tests and testing systems. Here’s a summary of some of the recent transactions affecting diagnostics.

Acquiring Company Target Deal Summary
Agilent Technologies Multiplicom, Belgiumbased molecular diagnostics firm spun off from Univ. of Antwerp in 2011
  • Price: €68 million ($70.6 million) in cash
  • AT to offer jobs to all 90 M employees
  • Lure is M’s BRCA Tumor MASTR Plus Dx test, first ovarian cancer companion test to get CE-IVD designation in Europe
Menarini-Silicon Biosystems Janssen Diagnostics
  • Price: Undisclosed
  • MSB acquires JD’s Cellsearch circulating tumor cell system for monitoring breast, prostate and colorectal cancers
  • Cellsearch is only breast cancer monitoring system approved by China FDA
Abbott Laboratories St. Jude Medical
  • $25 billion merger
  • European Commission OKs on antitrust grounds provided that: i. SJ divests Angio-Seal and Femoseal vascular closure assets; and ii. A divests Vado steerable sheath
  • All latter assets already slated for sale to Japanese firm Terumo for $1 billion
Takara Bio USA Holdings Rubicon Genomics
  • Price: $75 million
  • Helps T fortify position in pre-analytical genetic sample preparation and expand into in vitro fertilization
Grifols Hologic, Inc.’s blood screening assets
  • Price: $1.85 billion cash gross proceeds
  • G and H were partners in blood screening business with H doing R&D and manufacturing and G concentrating on commercialization
Abbott Laboratories Alere
  • Abbott sues to get out of $5.8 billion acquisition deal inked in Feb. (See LIR, Dec. 2016)
DNA Diagnostics Center Identigene, subsidiary of Sorenson Genomics
  • Price: Undisclosed
  • US/UK-based DDC acquires first company to sell in-home DNA paternity test collection kits in US mass retail stores including Rite Aid, CVS and Walmart
Boston Scientific Neovasc
  • 75 million in cash
  • BS acquires 15% equity stake + N’s advanced biological tissue business
Takara Bio USA Holdings (subsidiary of Takara Bio USA) Wafergen Biosystems
  • W shareholders approve merger announced in May
  • Price: Aggregate cash price based on a multiple of W’s 2016 calendar year revenues up— subject to $50 million cap
  • T to make two separate $2.5 million deposits in Jan.
Partner 1 Partner 2 Deal Summary
Henry Ford Health System Pathology and Laboratory Medicine Beckman Coulter Inc.
  • Purpose 1: Fully automate HF Hospital lab
  • Purpose 2: Modernize equipment at 12 other HF locations
Roche Pacific Biosciences
  • R ends 2013 $75 million agreement with PacBio to develop and commercialize diagnostic single-molecule sequencing system, effective Feb. 10, 2017
Agilent Genomics (the genomics arm of Agilent Technologies) Transcriptic (Bay Area diagnostic software firm)
  • Incorporates AG mutagenesis and cloning product lines to protocol library within T’s robotic cloud laboratory
  • Deal covers AG’s QuikChange site-directed mutagenesis kits
Novogene AITbiotech
  • Form NovogeneAIT Genomics Singapore, a joint venture to establish a whole-genome sequencing and bioinformatics center in Singapore
  • Joint venture will also collaborate with Genome Institute of Singapore in developing use of whole-genome sequencing for cancer diagnosis
Royal Phillips New York Medical College
  • Expansion of current partnership to develop IntelliSpace Genomics, an application that provides analysis workflows for pathologists, oncologists and researchers by integrating raw data from multiple sources
Evogen UCB
  • Collaboration to develop EvoScore START, a diagnostic test that measures a panel of blood-based protein biomarkers to distinguish between epileptic seizures and other events
Courtagen Life Sciences Certainty Health
  • Gives Courtagen exclusive access to CH’s mobile device-based data sharing platform for neurological diseases
  • Allows Courtagen to import its own neurological disease data into the platform
SystemOne Daktari Diagnostics
  • Partnership to improve workflow and identify operational efficiencies for catheterization and electrophysiology labs at UH Cleveland Medical Center
Property Owner Distributor Deal Summary
MDxHealth AceCGT Life Sciences Limited
  • Product: Prostate Cancer test
  • Territory: Hong Kong Macao
  • Exclusive
Dovetail Genomics LLC Tomy Digital Biology Co.
  • Product: Genome assembly services for researchers
  • Territory: Japan
  • Exclusive
Illumina Netherlands GenDx
  • Product: Next-generation sequencing instruments and reagents used for HLA sequencing
  • Territory: UK, Germany, Italy, Belgium, Netherlands, Luxembourg, Finland
  • Non-exclusive reselling rights
NantHealth Oncotest-Teva (subsidiary of Teva Pharmaceuticals)
  • Product: GPS Cancer molecular test
  • Territory: Israel
  • Exclusive reselling rights
NantHealth Lunatus
  • Product: GPS Cancer molecular test
  • Territory: Middle East, including UAE, Kuwait, Saudi Arabia, Oman, Bahrain, Qatar, Lebanon
  • Exclusive reselling rights
Argos Technologies Bibby Scientific
  • Products: Molecular and cell biology research products, storage and cryo-storage equipment
  • Territories: Europe, Middle East, Africa
Kapa Biosystems (owned by Roche) Merck
  • Products: Extends existing distribution alliance to include Kapa’s polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products
  • Territory: All markets except US, Japan and Brazil
  • Non-exclusive
Kapa Biosystems (owned by Roche) MilliporeSigma
  • Products: Extends existing distribution agreement to include Kapa’s polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products
  • Territory: All markets except US, Japan and Brazil
  • Non-exclusive
Senseonics Roche
  • Product: Eversense, S’s long-term implantable continuous glucose monitor
  • Territory: Extends current distributorship agreement covering Germany, Italy and the Netherlands to all of Europe (except Scandinavia), the Middle East (except Israel) and Africa
  • Exclusive sale, promotion and marketing rights
Licensor Licensee Deal Summary
Thermo Fisher Scientific Singulex
  • Product: TF’s BRAHMS PCT procalcitonin immunoassay
  • PCT used in US to assess critically ill patients’ risks of severe sepsis and septic shock and mortality risks of patients diagnosed with sepsis
  • FDA recently approved use of PCT for critically ill patients before admission to the ICU (previously, the patient had to be in the ICU already)
  • Non-exclusive: Thermo has also licensed PCT to Roche and Biomérieux
Labcyte Notable Labs
  • Product: L’s Echo acoustic liquid handling technology for personalizing drug therapy
  • NL will use Echo in its own labs to functionally assess effects of FDA-approved drugs on live primary cancer cells from individual patients
Epicentre (a subsidiary of Illumina) Lucigen
  • Products: Array of research products from E’s AmpliScribe, CopyControl, MaxPlax and TranforMax product lines
  • L to take over manufacture and sale
  • Exclusive
Property Owner Seller Deal Summary
Good Start Genetics Roche Diagnostics
  • Product: Gene Vu, GSG’s screening test to identify carriers of genetic disorders
  • R to sell Gene Vu along with its own Harmony prenatal fetal aneuploidy test
  • Territory: US
Edico Genome Amazon Web Services
  • Provides for E’s Dragen bioinformatics platform to be sold on new Amazon cloud-based instances

You have 2 articles left to view this month.

Your 3 Free Articles Per Month Goes Very Quickly!
Get a 3 month Premium Membership to
one of our G2 Newsletters today!

Click on one of the Newsletters below to sign up now and get unlimited access to all articles, archives, and tools for that specific newsletter!









Try Premium Membership